
Sign up to save your podcasts
Or


Biology is undergoing one of the biggest transformations in its history. AI is helping researchers analyse enormous datasets, predict protein structures, identify drug targets, and accelerate scientific discovery in ways that would have been difficult to imagine just a few years ago. But AI is not replacing scientists. If anything, it is making human expertise, judgement, and scientific rigour more important than ever.
In this conversation, we explore how the way science is done is changing. We discuss why so many promising discoveries never reach patients, why stronger collaboration between academia and industry matters, how breakthroughs such as AlphaFold are transforming biological research, and where AI is already delivering real-world results. We also ask some bigger questions: what can AI genuinely tell us about the human body, where are its limits, and are we sometimes confusing faster answers with deeper understanding?
Dr Filippo Dall'Armellina is a biochemist with a PhD from the University of Liverpool, where his research combined wet lab science with computational methods, focusing on protein modelling and the application of artificial intelligence and deep learning to protein–lipid interactions for drug target discovery.
Today, he advises pharmaceutical, biotechnology, and longevity companies on scientific and technical due diligence, clinical development strategy, and competitive landscape analysis, helping investors, founders, and leadership teams evaluate new technologies, therapeutic programmes, and emerging opportunities.
His career spans academia, healthcare operations, and science communication. He has authored peer-reviewed publications, with his work featured in Science and discussed on the Science Podcast. He has contributed to studies on the physiological effects of suborbital spaceflight in collaboration with the European Space Agency (ESA), managed NHS COVID-19 vaccination programme operations across North West England, and produced Neuro Podcases, a clinical neuroscience podcast ranked among the world's top 5%, featuring researchers and clinicians discussing neuroscience, clinical trials, and translational medicine.
Alongside his advisory work, Dr Dall'Armellina continues to collaborate with the University of Liverpool while supporting organisations working across biotechnology, pharmaceuticals, longevity, and human health.
Connect with Dr. Dall'Armellina on LinkedIn 🔗 Latest Publication
00:00 Welcome and Guest Intro
02:08 Filippo Background Journey
05:03 Skipping Masters to PhD
08:33 Embracing Research Chaos
12:39 Academia Industry Bridge
19:46 Why Discoveries Fail
23:44 AI in Structural Biology
32:15 AlphaFold Explained
36:58 Prediction vs Understanding
41:42 AI Meets Longevity
47:04 Next Five Years for AI
49:28 AI Hype and Missteps
53:07 Rapid Fire and Wrap Up
56:21 Final Takeaways Outro
Beyond Longevity interviews Kyle Holbert, COO and co-founder of Longevity Centres of America, about how unexplained fatigue, brain fog, depression, anxiety, joint pain and gut issues derailed his health despite a healthy lifestyle and years of searching for answers.
After seeing multiple GPs and therapists who either dismissed his symptoms or could not identify a cause, Kyle discovered he had severely low testosterone. Treatment with HCG led to a rapid improvement in his mental health and highlighted some of the limitations of time-constrained, symptom-focused healthcare.
When other symptoms persisted, he turned to biohacking and concierge medicine. A heavy metals provocation test later suggested chronic mercury toxicity, and a year of intensive chelation and IV-based treatment became a turning point in his recovery, ultimately leading him to leave the family construction business and move into longevity medicine.
The episode explores potential sources of mercury exposure, why individuals can respond very differently to similar toxic burdens, scepticism around many at-home detox products, and the importance of testing and clinician-guided treatment plans. Daphna and Kyle also discuss affordability, access to care, and the foundational role of movement, clean water, whole foods and targeted supplementation.
Website: https://www.thelcoa.com/longevity-unlocked-podcast/
Podcast: @longevityunlockedpod (https://www.instagram.com/longevityunlockedpod/)
Greenville, SC: @thelcgreenville (https://www.instagram.com/thelcgreenville/)
West Palm Beach, FL: @thelcfl (https://www.instagram.com/thelcfl/)
Dr K on Instagram: @theosteodoc
00:00 Podcast Setup
01:50 Kyle’s Early Life
04:26 Health Decline Begins
07:13 Dismissed by Doctors
12:20 Biohacking Breakthrough
15:40 Conference and Deeper Testing
17:38 Mercury Diagnosis and Chelation
19:38 Building Longevity Centres
20:30 Detox Timeline and Protocols
23:27 Sources of Heavy Metals
26:50 Generational Toxic Buildup
27:33 How Common Are Metals
28:12 Why Symptoms Vary
29:27 Detox Even If Fine
31:14 Detox Hype vs Reality
34:30 Making Care Affordable
40:52 How to Vet Clinics
43:40 Start With Basics
45:15 Avoid Longevity Traps
49:34 Supplements and Telehealth
53:09 Rapid Fire and Wrap
55:50 Final Takeaways
In this episode of Beyond Longevity, Daphna speaks with Nikolina Lauc, CEO and co-founder of GlycanAge, about glycobiology, immune ageing, and the role of chronic inflammation in ageing.
Nikolina explains why glycans, the complex sugar structures attached to our antibodies, may offer one of the clearest windows into the state of the immune system. The conversation explores “inflammaging”, the idea that chronic, low-grade inflammation may not simply be a consequence of ageing, but one of the forces actively driving it.
They discuss why antibody glycans may capture biological risk earlier than routine markers such as CRP, including research suggesting that glycan-based changes can appear years before standard blood tests show anything is wrong. Nikolina also explains how glycan testing may help predict disease risk and mortality and why repeat testing can reveal whether lifestyle changes are having a measurable biological effect.
Daphna and Nikolina also explore biological-age clocks, stress, high-performance lifestyles, exercise, pregnancy, menopause, and the strong influence of sex hormones, including HRT. The episode looks at why glycan testing is not yet part of routine clinical practice, the technical barriers involved, and the bigger question at the heart of preventive health: what should we do when we can see risk before disease appears?
GlycanAge showed very high reproducibility both in the blinded sample experiment run by Jamie Haywood at Alden Scientific, and independently in collaboration with Mike Snyder’s group at Stanford [Stanford paper reference]. Epigenetic clocks showed significant day-to-day oscillations in epigenetic age measurements [daily oscillation paper reference], which becomes important when trying to measure relatively small intervention effects over time.
We recently completed a UK Biobank study showing that the glycan markers we measure were more predictive of all-cause mortality than routine blood biochemistry alone; combining both further improved prediction performance (sharing the pre-print here).
We also published a large study across 42 cohorts and ~20,000 individuals showing that GlycanAge predicts all-cause mortality independently of traditional risk factors including BMI, CRP, hypertension, smoking, LDL, diabetes, cardiovascular disease history, and kidney markers. Across cohorts, every additional GlycanAge year was associated with roughly a 5-10% increase in all-cause mortality risk (sharing the pre-print here).
Another recent preprint evaluating epigenetic age clocks showed they do not substantially improve prediction of morbidity and mortality beyond information already captured through routine clinical blood biomarkers and standard risk factors [epigenetic clock preprint reference].
Background and key references are below:
GlycanAge intro
GlycanAge is a clinically validated biomarker platform originating from the work of Professor Gordan Lauc. Over the past five years, we've translated his research into a scalable clinical biomarker.
Today, GlycanAge is used in more than 2,000 private clinics worldwide and collaborates with leading academic and clinical partners including Mayo Clinic, Harvard Medical School, Northwestern Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, King Abdulaziz City for Science and Technology, Clinique La Prairie and many others, supporting both immune age tracking and disease-focused applications, particularly in cardiovascular and metabolic health.
Key references below:
Scientific Founder & Origins
Professor Gordan Lauc is one of the pioneers of human glycomics and co-founded the Human Glycome Project (with Harvard’s Richard Cummings). He discovered GlycanAge as one of the first systemic measures of biological aging based on immune glycosylation.
A New Class of Biological Clock
GlycanAge is the first inflammaging clock, measuring chronic low-grade inflammation through IgG glycosylation, independent of acute events.
Prediction of Morbidity & Mortality
Glycan signatures predict multiple future clinical outcomes; I'm sharing a review (Biotechnology Advances 2023) linking IgG glycans to 72+ disease indications, where we see specific glycan shifts up to 10 years before symptoms onset or clinical diagnosis.
Cardiovascular disease
Diabetes
Cross-Population Validation
Beyond European cohorts: in a study of 27 populations across 14 countries, IgG glycosylation patterns tracked with age/sex and correlated with life expectancy and national health indices (HDI, SDG, MDG), demonstrating validity across genetically and environmentally diverse populations (Aging 2020).
Interventions GlycanAge Responds To:
00:00 Welcome to Beyond Longevity
00:41 Meet Nicolina Loud
02:33 Glycans Explained Simply
05:02 Glycans Everywhere in Biology
06:46 Inflammaging and Ageing Theory
08:37 Why Glycans Beat Standard Markers
12:10 From Lab Discovery to Company
15:51 What Glycan Age Measures
17:57 Does Biological Age Matter
20:41 Inequality Stress and Ageing
24:37 Athletes and High Performer Costs
28:04 Which Ageing Clocks to Trust
29:35 Variability and Real-World Example
34:20 Epigenetic Clocks Mechanism Unknown
35:03 Epigenetic Clock Limits
36:36 Combining Clocks Wisely
38:28 Longitudinal Testing Strategy
39:44 Personalised Interventions
42:14 Retesting Cadence
44:17 Pregnancy Immune Reset
45:53 Hormones and Glycan Age
51:30 Why Not Routine Care
54:45 Future of Prevention
58:49 Rapid Fire Takeaways
01:00:57 Young Plasma Frontier
01:04:34 Closing Reflections
Daphna sat down with Alan Graves, founder of DoNotAge, for an in-depth conversation about what it takes to make longevity science more credible, more collaborative and more accessible.
After a serious health decline in his late twenties, Alan entered the longevity field after learning that ageing may be more malleable than he had once thought. He went on to build DoNotAge as a self-funded health research organisation, using consumer supplements to help fund ageing research, support external labs and emerging researchers, provide high-purity ingredients for independent studies, and translate complex science into language people can actually understand.
The conversation covers why longevity science is still difficult to access, why the supplement industry has a credibility problem, and how marketing, underdosing and weak “science-backed” claims have made it hard for consumers to know what to trust.
Alan also discusses the realities of clinical trials, why they are slow and expensive, and the studies DoNotAge is currently supporting or planning, including work around spermidine, NAD, Crohn’s disease, berberine and biological age clocks.
In striving to make longevity easier and more practical, Alan has also introduced a one-a-day sachet designed to simplify adherence. They also explore his focus on sirtuin 6 activation, DoNotAge’s free London conference, and the wider aim of making longevity more affordable, practical and collaborative.
DoNotAge.org is a health research organisation.
You can learn more at https://routine.donotage.org
00:00 Welcome and Guest Intro
02:52 Alan’s Unlikely Origin Story
04:34 From Self-Experiment to Do Not Age
06:45 Funding Gap and New Model
08:12 Democratising Longevity Science
09:48 Research Company Not Supplements
11:09 Why Clinical Trials Take Years
12:50 How Do Not Age Is Structured
15:09 Supporting Labs Worldwide
18:01 Supplement Industry Credibility Crisis
21:01 How Consumers Verify Claims
22:42 Stepping Down as CEO
25:11 Choosing Which Research to Fund
26:45 Upcoming Trials and What’s Next
28:10 Basics Before Supplements
31:43 Testing and Biological Age
33:24 The One-a-Day Sachet Idea
36:03 Clinical Trials Pipeline
36:55 Making Longevity Affordable
39:58 Pricing Ethics and Dosage
41:33 Hype vs Evidence in Longevity
44:51 Who Needs Supplements When
46:55 Free Unbiased Science Conference
53:02 What Excites Him Next
54:08 SIRT6 Activator Deep Dive
58:30 Why Healthcare Won’t Adopt It
01:01:44 Boxing, Balance, and Ageing Goals
01:04:41 Rapid Fire and Wrap Up
01:07:15 Host Takeaways and Conclusion
In this episode of Beyond Longevity, Daphna speaks with Dr David Cox, a health journalist (BBC, The Guardian, The Telegraph, NBC News and others), who holds a PhD in neuroscience from the University of Cambridge and is the author of The Age Code, about how diet, ultra-processed foods and the modern food environment shape biological ageing.
Dr David argues that the longevity conversation often focuses too heavily on future drug breakthroughs, supplements and biohacking, while overlooking lower-hanging fruit that could already have a meaningful impact on long-term health. He explains why reducing ultra-processed foods, increasing fibre intake and paying closer attention to micronutrients such as vitamin K may matter far more than many people realise.
The conversation explores gut ageing and its relationship with immune ageing, possible drivers behind the rise in early-onset cancers, and practical lifestyle strategies that may support healthier ageing. These include slow cooking, eating more protein and calories earlier in the day, lowering dietary acid load through fruits, vegetables and herbs, and the role omega-3s may play in long-term health.
Daphna and Dr David also discuss biological ageing tests, visceral fat, kidney health markers, the limitations of CGMs for the average person, exercise mimetics, affordability within longevity medicine, and whether governments should take a far more active role in tackling the everyday drivers of chronic disease and accelerated ageing.
The Age Code: https://www.amazon.co.uk/dp/0008708878
https://www.instagram.com/drdavidcoxhealth
https://www.linkedin.com/in/dr-david-cox-6b219666
00:00 Welcome and Guest Intro
02:00 From PhD to Journalism
03:17 Science Scepticism and Nuance
05:22 Trust Crisis in Health
06:44 Protein Hype vs Fibre
07:40 Micronutrients Matter
09:07 Inside The Age Code
10:50 Early Onset Cancer Clues
12:38 Gut Ageing Explained
14:49 Ten Nutritional Stressors
17:55 Ultra Processed Food Reality
19:32 Personal Choice vs Policy
23:33 Longevity Focus Misplaced
25:00 Ageing Tests and Omega 3
27:39 Advice for Any Budget
29:48 Sauna Protocols
31:04 Metabolomics Health Snapshots
33:16 Testing Anxiety and Rule of Three
35:41 His Own Biomarker Wake Up
37:41 Best and Overrated Biomarkers
41:25 Exercise Mimetic Drugs Debate
48:05 Government and Ageing Strategy
50:23 Kitchen Takeaways and Seaweed
53:18 Rapid Fire Round
56:08 Final Reflections and Outro
Supplements promise a lot: mitochondrial support, better brain health, healthier gut function, anti-ageing benefits and more.
But how much of that is real science, and how much is simply clever wording on a label?
In this episode of Beyond Longevity, Dr Luke Bucci, PhD, Chief Scientific Officer at Juvenon, brings both a scientist’s eye and decades of experience in the supplement industry to one of the most confusing areas of longevity.
Dr Luke explains the difference between a product being described as “science-backed” and one that is supported by meaningful human clinical evidence. He also discusses why the dose, form and standardisation of an ingredient matter, and why “fairy-dusting” fashionable ingredients into a formula can make a product sound far more proven than it really is.
We talk about bioavailability, absorption, the gut microbiome, and why feeling stimulated is not the same as supporting mitochondrial health. Dr Luke also explains why creatine has moved beyond the gym, why blood flow and nitric oxide matter as we age, and how nutrients such as magnesium, vitamin D3, omega-3s, polyphenols and CoQ10 fit into a more thoughtful approach to supplementation.
This is a practical and refreshingly honest conversation about how to read beyond the label, ask better questions, and think more clearly about what supplements can, and cannot, do.
Links:
Instagram: https://www.instagram.com/juvenonwellness
Facebook: https://www.facebook.com/Juvenon/
Website: https://juvenon.com/
00:00 Welcome and Guest Intro
01:53 Dr Bucci Origin Story
03:26 Science vs Marketing Today
04:44 Science Backed vs Clinical
09:14 Fairy Dusting Exposed
11:05 Bioavailability Reality Check
14:15 Standardisation and Sourcing
22:03 Gut Microbiome Benefits
24:30 Testing and Trial Periods
27:33 Longevity Trend Explained
30:35 Mitochondria 101
34:14 Stimulants vs Real Energy
40:47 Stimulant Band Aid Trap
41:51 Creatine Beyond The Gym
45:08 Creatine Dosing And Safety
47:11 Creatine For Brain Ageing
50:53 Why Blood Flow Declines
53:42 Nitric Oxide Basics
57:44 Arginine Silicate Explained
01:04:45 Polyphenols And Nitrates
01:06:53 My Essential Supplements
01:11:36 Rapid Fire Wisdom
01:13:49 Episode Takeaways
This week on Beyond Longevity, I am joined by Dr Herna de Wit, CEO and Founder of Omnisci Consulting, with a PhD in Biochemistry and an LLB in Law.
Dr Herna brings a very unusual and valuable combination to the longevity conversation: deep scientific training, legal expertise and hands-on experience advising companies in the health, biotech and longevity space.
Longevity is full of exciting science, but it is also a field where marketing can move faster than evidence. In this episode, we ask a simple but important question: how do we separate what is genuinely credible from what merely sounds convincing?
Dr Herna shares her five-point “scientific sanity check” for evaluating longevity products, supplements and protocols. We discuss why human RCT data matters more than animal or cell studies, why dosage and bioavailability are often overlooked, what biological age clocks can and cannot tell us, and why safety, third-party testing, and regulatory discipline are essential in a fast-moving market.
We also look at longevity from the perspective of investors and company builders. What are the red flags? What makes a claim scientifically weak? And why does defensible intellectual property matter far beyond simply having a patent?
Dr Herna explains how companies can think more intelligently about protectability, including through delivery systems, synergistic formulations, data, know-how and clearer scientific positioning.
The conversation then turns to South Africa, a market that many listeners may not immediately associate with longevity, but one that raises fascinating questions. We discuss medical tourism, scientific talent, regulatory realities, affordability and whether South Africa could carve out a distinctive role in the global healthspan conversation.
Finally, we speak about one of the most important tensions in longevity: if the science advances, who actually gets access? Is longevity already becoming another layer of privilege, or can the field develop in a way that is more credible, more inclusive and more useful?
This is a conversation about evidence, accountability and the future of a field that urgently needs both excitement and discipline.
Links:
https://www.linkedin.com/in/herna-de-wit-phd-llb/
https://linktr.ee/drherna.omnisci
00:00 Show Intro and Guest
02:41 Dr Herna’s Unusual Path
04:29 What She Does Today
06:13 Five Point Science Audit
11:17 Investor Red Flags
15:31 IP Beyond Patents
20:12 Open Science vs Profit
24:35 Founder IP Strategy
32:54 Global Longevity Hotspots
33:42 South Africa Opportunity
36:33 Access and Inequality
43:12 Regulation and Innovation
46:20 How to Work With Dr Herna
50:02 Rapid Fire Questions
52:20 Final Takeaways Outro
On Beyond Longevity, Dr Filippo Ongaro, medical doctor, entrepreneur, and strategic advisor, shares how nearly eight years working with astronauts at the European Space Agency shaped the way he thinks about ageing.
In space, the body can lose muscle, bone and resilience at a frightening speed. Stress, sleep disruption, nutrition, movement and circadian misalignment are not lifestyle details. They become central medical issues. For Dr Filippo, space became a kind of accelerated ageing model, showing in fast-forward what happens when the systems that keep us strong begin to break down, and why exercise and nutrition are such powerful countermeasures.
After leaving ESA, Dr Filippo opened one of Italy’s early anti-ageing and functional medicine centres. But over time, he came to believe that the biggest obstacle in longevity is not simply knowledge, testing, or more biomarkers. It is the behaviour gap. People often know what they should be doing. The harder question is why they do not follow through.
Together with his wife Sonya, he shifted from one-to-one clinical work into education, coaching, professional training and strategic advisory, with a focus on making longevity more accessible, affordable and practical, including through pharmacy-based pathways.
In this conversation, he argues that longevity should focus on healthspan, avoid overpromising, build trust, start earlier with younger people, and move beyond fear of death towards purpose, identity and the joy of life
links: www.metodo-ongaro.com
https://www.linkedin.com/in/dr-filippo-ongaro/
Dr. Filippo Ongaro
00:00 Welcome and Guest Intro
02:53 From ESA to Longevity
05:07 Space as Accelerated Ageing
07:40 Countermeasures and Behaviour Gap
09:53 Mindset Over Biohacking
14:24 Mission Drives Discipline
17:22 Delayed Gratification Science
20:37 Building Anti-Ageing Practice
22:11 Why People Don't Follow Through
24:31 Who Wanted Anti-Ageing Help
28:16 Pivot to Education at Scale
31:53 Training Health Professionals
32:24 Scaling Impact Through Partners
33:27 Broadening the Audience
34:36 Affordable Longevity Access
37:11 Institutions and Mass Market
40:14 Business Advice for Clinicians
43:26 Hype, Trust, and PR
45:07 Fear Versus Joy of Life
47:16 Identity Driven Change
53:24 Future of Longevity Market
56:00 Healthspan Over Lifespan
57:58 Rapid Fire and Wrap Up
01:00:18 Final Episode Takeaways
Michael A. Clinton, former President of Hearst Magazines.
Michael spent four decades at the top of the publishing world, including as President and Publishing Director of Hearst Magazines, before turning his attention to one of the biggest questions of our time. If many of us are likely to live longer than previous generations, how do we make the second half of life not just longer, but more intentional, productive and meaningful?
In this episode of Beyond Longevity, Michael discusses the ideas behind his book ROAR and his framework for rethinking later life. ROAR stands for Reimagine, Own your numbers, Action plan and Relationships, and it became the foundation for Roar Forward, his B2B platform advising organisations on the fast-changing 50-plus consumer.
The conversation explores why Michael believes we need to shift the language from “ageing” to “longevity”, how culture and business are slowly beginning to respond, and why institutions, employers and policymakers still have a long way to go.
Michael also previews ideas from his new book, Longevity Nation, which looks at the people, companies and innovations reshaping what longer lives could mean. He raises important concerns about inequality, access and the growing number of products making claims that are not always backed by evidence.
This is also a very personal conversation. Michael reflects on his working-class roots in Pittsburgh, the moment that changed how he thought about identity and reinvention, and why the longest chapter of life may be the one most people have planned for the least.
The episode also touches on the economic power of the $8.3 trillion 50-plus consumer, why this market is still widely misunderstood, and the one longevity habit Michael believes anyone can begin with, regardless of income.
Links:
Longevity Nation
ROAR forward
00:00 Welcome and Guest Intro
02:19 Early Life and First Memory
03:17 Ambition and Upbringing
05:12 Finding His Career Path
06:29 Hearst Lessons on Identity
09:22 ROAR Framework Explained
13:29 Longevity Economy for Business
16:19 Language and Pro Age Messaging
18:43 Brands and Countries Adapting
21:55 Fear and Reinvention Mindset
22:59 Purposeful Second Act
23:38 Reimagineer Stories
24:37 Why Longevity Nation
27:33 Inequality and Access
30:13 America and 100 Year Life
33:18 Policy Gaps to Fix
35:53 Hope Worries Takeaway
40:16 Rapid Fire Round
42:42 Longevity Habits and Myths
45:05 Closing Reflections
What does good prevention actually look like, and is the longevity industry helping people live better, or simply making health feel more complicated?
In this episode of Beyond Longevity, Daphna speaks with Niko Hems, Operations Lead at YEARS, a longevity clinic in Berlin, Germany.
Niko brings a rare perspective to the conversation. He works inside the longevity field, but he is not afraid to challenge it. He believes deeply in prevention, yet he is sharply aware of where the industry can go wrong, from over-testing and over-promising to fringe science and the uncomfortable gap between those who can afford cutting-edge healthcare and those who are still struggling to access the basics.
His own story makes this especially interesting. At 13, Niko became fascinated by nutrition and fitness while trying to gain weight and feel better in his body. Years later, after completing a Master’s in Longevity Sciences and working inside one of Germany’s leading longevity clinics, he put himself through the kinds of tests many people now associate with the future of health, including genome sequencing, microbiome analysis and more than 200 biomarkers.
The result was not quite what he expected. Instead of clarity, much of it created anxiety. Instead of answers, it raised a harder question: when does prevention become too much?
This is a refreshingly honest conversation about the promises and problems of modern longevity, the tests that help versus the ones that confuse, the basics that still matter most, and what a more credible, useful and accessible version of prevention could look like.
Niko Hems Head of Growth at YEARS.
Host of Return on Health podcast.
Links:
https://nikohems.de
https://www.linkedin.com/in/niko-hems/
https://returnonhealth.de/
00:00 Podcast intro and themes
01:52 Nico’s path into longevity
03:37 Defining longevity and healthspan
04:47 Peakspan explained
06:26 Basics that move the needle
08:32 When testing becomes anxiety
10:07 Inside the Years clinic model
14:26 Cost access and inequality
15:58 Who buys high-end programs
17:55 What 16K actually includes
20:43 Why behaviour change is hard
24:07 Are we really getting healthier
26:04 Lifespan hype vs healthspan focus
28:25 Prevention Over Testing
29:23 Affordable Core Diagnostics
30:50 Why Healthcare Lags
32:58 Fixing Incentives
37:37 Longevity Branding Problem
41:09 Basics That Move Needle
43:28 Free High Impact Habits
46:22 AI And Longevity Future
52:04 Rapid Fire Wrap Up
53:42 Final Takeaways
From the publisher's feed